AVJ-514 Japan Trial

NCT ID: NCT02520310

Last Updated: 2021-06-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-07
• Study Completion Date: 2021-05-31

Brief Summary

The objective of the study is to confirm the reproducibility of the evidence of safety and efficacy of AVJ-514 System technology in Japanese subjects who have been deemed difficult for mitral valve surgery by the local site heart team.

Detailed Description

This study is a prospective, multi-center, single-arm clinical evaluation of the AVJ-514 System for the treatment of symptomatic chronic severe mitral regurgitation (MR) in Japanese subjects deemed difficult for mitral valve surgery by the local site heart team.

Patients will be evaluated at baseline, discharge, 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years in Japanese Medical Centers.

Conditions

Mitral Stenosis With Insufficiency; Functional Mitral Regurgitation; Mitral Insufficiency; Mitral Valve Incompetence; Mitral Valve Regurgitation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AVJ-514

The AVJ-514 system

Group Type: EXPERIMENTAL

AVJ-514

Intervention Type: DEVICE

Patients receiving AVJ-514 device

Interventions

AVJ-514

Patients receiving AVJ-514 device

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age 20 years or older.

2. Symptomatic moderate-to-severe (3+) or severe MR (4+) chronic Degenerative Mitral Regurgitation (DMR) or Functional Mitral Regurgitation (FMR) determined by assessment of a qualifying transthoracic echocardiogram (TTE) obtained within 90 days and transesophageal echocardiogram (TEE) obtained within180 days prior to subject registration, with MR severity based principally on the TTE study and confirmed by the Echocardiography Core Laboratory (ECL). The ECL may request a TEE.

3. Left Ventricular Ejection Fraction (LVEF) is ≥ 30％ within 90 days prior to subject registration, assessed by the site using any one of the following methods: echocardiography, contrast left ventriculography, gated blood pool scan or cardiac magnetic resonance imaging (MRI). Note: The method must provide a quantitative readout (not a visual assessment).

4. New York Heart Association (NYHA) classification is class II, class III, or ambulatory class IV.

5. Subject is deemed difficult for mitral valve surgery due to either Society of Thoracic Surgery (STS) surgical mortality risk for mitral valve replacement of ≥ 8% OR due to the presence of one of the following risk factors:

• Porcelain aorta or mobile ascending aortic atheroma
• Post-radiation mediastinum
• Previous mediastinitis
• Functional MR with LVEF < 40%
• Over 75 years old with LVEF < 40%
• Re-operation with patent grafts
• Two or more prior cardiothoracic surgeries
• Hepatic cirrhosis
• Other surgical risk factor(s)

6. Mitral valve area ≥ 4.0 cm2 assessed by ECL based TTE within 90 days prior to subject registration. The ECL may request a TEE.

7. Left Ventricular End Systolic Dimension (LVESD) is ≤ 60mm assessed by site based on the TTE obtained within 90 days prior to subject registration.

8. The primary regurgitant jet is non-commissural based on TEE, and in the opinion of the AVJ-514 implanting investigator can successfully be treated by the AVJ-514. If a secondary jet exists, it must be considered clinically insignificant.

9. Transseptal catheterization and femoral vein access is determined to be feasible by the treating physician.

10. The subject or the subject's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board of the respective clinical site.

Exclusion Criteria

1. LVEF is < 30%

2. Leaflet anatomy which may preclude AVJ-514 implantation, proper positioning on the leaflets or sufficient reduction in MR by the AVJ-514 based. This evaluation is based on TEE evaluation of the mitral valve within 180 days prior to subject registration and includes:

• Insufficient mobile leaflet available for grasping with the AVJ-514 device
• Lack of both primary and secondary chordal support in the grasping area
• Evidence of significant calcification in the grasping area
• Presence of a significant cleft in the grasping area

3. Life expectancy < 1 year due to associated non-cardiac co-morbid conditions

4. Need for emergent or urgent surgery for any reason

5. Prior open heart mitral valve leaflet surgery or any currently implanted prosthetic mitral valve or any prior transcatheter mitral valve procedure.

6. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.

7. Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e. noncompliant, perforated).

8. Untreated clinically significant coronary artery disease requiring revascularization or significant myocardial ischemia or evidence of an acute myocardial infarction in the prior 90 days of registration.

9. Cerebrovascular accident within 180 days prior to registration

10. Severe symptomatic carotid stenosis (> 70% by ultrasound)

11. Any cardiac surgery within 180 days prior to registration

12. Percutaneous coronary intervention (PCI) within the last 30 days prior to registration

13. Implant of Cardiac Resynchronization Therapy (CRT), Cardiac Resynchronization Therapy with Cardioverter Defibrillator (CRT-D) pacemaker or Implantable Cardioverter Defibrillator (ICD)within the last 30 days prior to registration.

14. Transcatheter aortic valve replacement (TAVR) within the last 30 days prior to registration.

15. Severe tricuspid regurgitation or aortic valve disease requiring surgical treatment.

16. In the judgment of the Investigator, the femoral vein cannot accommodate a 24 F catheter or presence of ipsilateral deep vein thrombosis (DVT).

17. Hemodynamic instability defined as systolic pressure < 90 mmHg without afterload reduction drug or cardiogenic shock or intra-aortic balloon pump.

18. History of bleeding diathesis or coagulopathy or subject will refuse blood transfusions.

19. Active infections requiring current antibiotic therapy (if temporary illness, patients may enroll at least 14 days after discontinuation of antibiotics). Patients must be free from infection prior to treatment. Any required dental work should be completed a minimum of 21 days prior to treatment.

20. Intravenous drug abuse or suspected inability to adhere to follow-up.

21. Patients in whom TEE is contraindicated.

22. A known hypersensitivity or contraindication to study or procedure medications which cannot be adequately managed medically.

23. In the judgment of the Investigator, subjects in whom the presence of a permanent pacemaker or pacing leads would interfere with placement of the test device or the placement of the test device would disrupt the leads.

24. Subject intends to participate in any other investigational or invasive clinical study within a period of 1 year following the AVJ-514 procedure.

25. Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).

26. In the opinion of the investigator or designee, subject is unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.

27. In the opinion of the anesthesiologist, general anesthesia is contraindicated.

28. Pregnant or planning pregnancy within next 1 year.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott Medical Devices

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ryohei Yozu, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Keio University

Morimasa Takayama, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Sakakibara Heart Institute

Peter Staehr, MD

Role: STUDY_DIRECTOR

Abbott Vascular, Inc.

Locations

Shonan Kamakura General Hospital

Kanagawa, , Japan

Sendai Kosei Hospital

Miyagi, , Japan

National Cerebral and Cardiovascular Center

Osaka, , Japan

Keio University Hospital

Tokyo, , Japan

Sakakibara Heart Institute

Tokyo, , Japan

Tokyo Women's Medical University Hospital

Tokyo, , Japan

Countries

Japan

References

Hayashida K, Yasuda S, Matsumoto T, Amaki M, Mizuno S, Tobaru T, Jujo K, Ootomo T, Yamaguchi J, Fukuda K, Saito S, Foster E, Qasim A, Kitakaze M, Yozu R, Takayama M. AVJ-514 Trial - Baseline Characteristics and 30-Day Outcomes Following MitraClip(R) Treatment in a Japanese Cohort. Circ J. 2017 Jul 25;81(8):1116-1122. doi: 10.1253/circj.CJ-17-0115. Epub 2017 Mar 17.

Reference Type: DERIVED

PMID: 28321004 (View on PubMed)

Other Identifiers

AVJ-514

Identifier Type: -

Identifier Source: org_study_id